FDA to review efficacy issues in morning-after pill

Share this article:

HRA Pharma, a French drug manufacturer, says that its levonorgestrel-based emergency contraceptive, Norlevo,  loses efficacy in women who weigh over 165 pounds, and is ineffective in women who weigh over 176 pounds. The drugmaker requested permission to update its label from EU regulators.

FDA, responding to a query from Reuters on Monday, said they are "currently reviewing the available and related scientific information on this issue, including the publication upon which the Norlevo labeling change was based," and that "the agency will then determine what, if any, labeling changes to approved emergency contraceptives are warranted."

A spokeswomen for HRA Pharma told Mother Jones that upping the dosage does not solve the problem.

Plan B, sold by Teva Pharmaceuticals, and generic versions thereof, are also levonorgestrel-based emergency contraceptives.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.